Disseminated mycobacteria chelonae infection in a kidney-pancreas transplant recipient: A case report and review of the literature
- PMID: 27900974
- DOI: 10.4103/1319-2442.194681
Disseminated mycobacteria chelonae infection in a kidney-pancreas transplant recipient: A case report and review of the literature
Abstract
A 40-year-old male with a long-standing history of type 1 diabetes with end-stage renal failure underwent combined kidney-pancreas (KP) transplant from a standard criteria donor. Post-operative course was uncomplicated with good primary function of both transplant grafts. Induction was with thymoglobulin and maintenance immunosuppression was with tacrolimus, mycophenolate mofetil and prednisolone. Nine weeks post-transplant, the patient developed dysfunction of both grafts. Panel reactive antibody testing revealed that the patient had developed a de novo donor-specific antibody and considering an antibody-mediated rejection the patient was treated with intravenous pulse methyl prednisone 500 mg ×3 doses, IV immunoglobulin 2 mg/kg in two divided doses, and ATG 7 mg/kg (total dose of 700 mg). In addition, his baseline immunosuppression was increased. Cr decreased to baseline levels, and blood sugars were in the range of 7-8 mmol/L, serum amylase normalized to 63 U/L, and the patient was discharged home. Nine days post-discharge, the patient presented to the hospital with a five-day history of fever, pain, and swelling in the left knee along with subcutaneous, erythematous, tender, nodular lesions in both legs and both arms. Skin biopsy showed Ziehl-Neelsen stain positive rods and biopsy culture and blood culture grew Mycobacteria chelonae. Antimicrobials were switched to azithromycin 500 mg OD, moxifloxacin 400 mg OD, and linezolid 600 mg BID and baseline immunosuppression was reduced to tacrolimus trough target 8-10 ng/mL and MMF to 250 mg BID. The patient gradually improved and was discharged after 28 days in the hospital. Six weeks following the diagnosis of nontuberculous mycobacteria infection, the patient's pancreas graft failed, presumably due to reduction in immuno-suppression and he is now back on insulin treatment. His renal graft continued to function well. Although rapidly growing mycobacterial infections are rare among transplant recipients, it should be suspected among those who have received augmented immunosuppression. Blood cultures and skin biopsy of the lesions are important to establish the diagnosis.
Similar articles
-
Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.Clin Transplant. 1997 Aug;11(4):299-312. Clin Transplant. 1997. PMID: 9267719 Clinical Trial.
-
Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.Transplantation. 2007 May 27;83(10):1324-9. doi: 10.1097/01.tp.0000264189.58324.91. Transplantation. 2007. PMID: 17519781
-
Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.Clin Transplant. 2018 Jun;32(6):e13265. doi: 10.1111/ctr.13265. Epub 2018 May 12. Clin Transplant. 2018. PMID: 29676018 Clinical Trial.
-
Thymoglobulin-Resistant T-Cell-Mediated Acute Rejection in a Pregnant Renal Transplant Recipient: Case Report and Review of the Literature.Exp Clin Transplant. 2019 Jan;17(Suppl 1):159-163. doi: 10.6002/ect.MESOT2018.P38. Exp Clin Transplant. 2019. PMID: 30777545 Review.
-
Pregnancy Management and Outcomes in a Small Bowel, Pancreas, and Liver Transplant Recipient: A Case Report and Literature Review.Am J Case Rep. 2024 Nov 15;25:e945914. doi: 10.12659/AJCR.945914. Am J Case Rep. 2024. PMID: 39543857 Free PMC article. Review.
Cited by
-
Tacrolimus Pharmacotherapy: Infectious Complications and Toxicity in Organ Transplant Recipients; An Updated Review.Curr Drug Res Rev. 2025;17(2):301-310. doi: 10.2174/0125899775259326231212073240. Curr Drug Res Rev. 2025. PMID: 38151846 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical